- Home
- ASMB vs NXC Comparison
ASMB vs NXC Comparison
Compare ASMB & NXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- NXC
- Stock Information
- Founded
- ASMB 2005
- NXC 1992
- Country
- ASMB United States
- NXC United States
- Employees
- ASMB N/A
- NXC N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- NXC Investment Managers
- Sector
- ASMB Health Care
- NXC Finance
- Exchange
- ASMB Nasdaq
- NXC Nasdaq
- Market Cap
- ASMB 130.2M
- NXC 82.0M
- IPO Year
- ASMB 2010
- NXC N/A
- Fundamental
- Price
- ASMB $18.14
- NXC $13.02
- Analyst Decision
- ASMB Strong Buy
- NXC
- Analyst Count
- ASMB 3
- NXC 0
- Target Price
- ASMB $33.00
- NXC N/A
- AVG Volume (30 Days)
- ASMB 41.3K
- NXC 17.5K
- Earning Date
- ASMB 08-07-2025
- NXC 01-01-0001
- Dividend Yield
- ASMB N/A
- NXC 3.97%
- EPS Growth
- ASMB N/A
- NXC N/A
- EPS
- ASMB N/A
- NXC 0.19
- Revenue
- ASMB $32,154,000.00
- NXC N/A
- Revenue This Year
- ASMB $0.04
- NXC N/A
- Revenue Next Year
- ASMB N/A
- NXC N/A
- P/E Ratio
- ASMB N/A
- NXC $70.47
- Revenue Growth
- ASMB 148.33
- NXC N/A
- 52 Week Low
- ASMB $7.75
- NXC $11.86
- 52 Week High
- ASMB $19.93
- NXC $13.70
- Technical
- Relative Strength Index (RSI)
- ASMB 68.18
- NXC 57.30
- Support Level
- ASMB $17.45
- NXC $12.97
- Resistance Level
- ASMB $18.92
- NXC $13.20
- Average True Range (ATR)
- ASMB 0.87
- NXC 0.13
- MACD
- ASMB -0.05
- NXC 0.03
- Stochastic Oscillator
- ASMB 74.68
- NXC 62.50
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.